Dorzolamide (Ciplasopt, Gozopt)
Dorzolamide
Cipla Medpro (Pty) Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- Cipla Medpro (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ciplasopt EACH 5,0 ml SOLUTION CONTAINS DORZOLAMIDE HYDROCHLORIDE 111,25 mg | Not listed | 45107745/15.4/1077 | Cancelled | Not determined | None |
| Gozopt EACH 5,0 ml SOLUTION CONTAINS DORZOLAMIDE HYDROCHLORIDE 111,25 mg | Not listed | 45108045/15.4/1080 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Dorzolamide
Consolidated Schedules 06 July 2026, line 3486
7 of 21 approved products with this ingredient carry S4 on their leaflet.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(4S,6S)-4-(Ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
Drag to rotate. Structure from PubChem CID 5284549.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.